nach oben

European Journal of Nutrition

Erschienen in:

01.09.2010 | Original Contribution

In vitro interactions between aged garlic extract and drugs used for the treatment of cardiovascular and diabetic patients

verfasst von: Katja Berginc, Simon Žakelj, Albin Kristl

Erschienen in: European Journal of Nutrition | Ausgabe 6/2010

Einloggen, um Zugang zu erhalten

Abstract

Background

Disease preventing effects gained by garlic consumption have been recognized since early period of history, making commercially available garlic supplements attractive to the general public. Possible pharmacokinetic interactions which could occur between applied drugs and aged garlic extract (AGE) are unknown.

Aim

To test in vitro impact of some garlic phytochemicals on P-glycoprotein (Pgp), the most recognized efflux transporter, and the effect of AGE on passive membrane permeability, absorptive and secretory intestinal transporters.

Methods

Rat small intestine and Caco-2 cell monolayers, mounted in side-by-side diffusion chambers were used.

Results

Hydrophilic sulphur compounds increased Pgp mediated Rhodamine 123 (Rho123) efflux, whereas the lipophilic ones increased Pgp efflux through rat ileum but not through Caco-2 cell monolayers. Increased activities of secretory (Pgp, multidrug-resistance associated protein 2) and absorptive (monocarboxylate transporter 1, organic anion transporting polypeptide) transporters involved in drug absorption were observed in rat small intestine and Caco-2 cell monolayers in the presence of AGE. Transport of drugs mediated by breast cancer resistance protein and H⁺-oligopeptide transporter 1 was activated in rat intestine but inhibited through Caco-2 cells. Passive membrane permeability of tested compounds remained unaltered through rat small intestine, while significant changes were observed with Caco-2 cell monolayers.

Conclusions

Due to the observed in vitro pharmacokinetic interactions between AGE and investigated cardiovascular, antidiabetic and antiviral drugs, in vivo absorption changes are possible, but the magnitude of change depends on the most profound process involved (influx, efflux, passive diffusion) in compounds permeability.

Rivlin RS (2001) Historical perspective on the use of garlic. J Nutr 131(3S):951S–954S

Agarwal KC (1996) Therapeutic actions of garlic constituents. Med Res Rev 16:111–124CrossRef

Ejaz S, Woong LC, Ejaz A (2003) Extract of garlic (Allium Sativum) in cancer chemoprevention. Exp Oncol 25:93–97

Yeh YY, Liu L (2001) Cholesterol-lowering effect of garlic extracts and organosulfur compounds: human and animal studies. J Nutr 131(3S):989S–993S

Amagase H (2006) Clarifying the real bioactive constituents of garlic. J Nutr 136:716S–725S

Fugh-Berman A (2000) Herb-drug interactions. Lancet 355:134–138CrossRef

Wu CY, Benet LZ (2005) Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutical drug disposition classification system. Pharm Res 22:11–23CrossRef

Deferme S, Augustijns P (2003) The effect of food components on the absorption of Pgp substrates: a review. J Pharm Pharmacol 55:153–162CrossRef

Foster B, Foster M, Vandenhoek S, Krantis A, Budzinski JW, Arnason JT, Gallicano KD, Choudri S (2001) An in vitro evaluation of human cytochrome P450 3A4 and P-glycoprotein inhibition by garlic. J Pharm Pharmaceut Sci 4:176–184

10.

Lancaster JE, Boland MJ (1989) Flavor Biochem. In: Brewster JL, Rabinowitch HD (eds) Onions and allied crops: food science and minor crops. CRC Press, USA, pp 34–54

11.

Jones MG, Hughes J, Tregova A, Milne J, Tomsett AB, Collin HA (2004) Biosynthesis of the flavour precursors of onion and garlic. J Exp Bot 55:1903–1918CrossRef

12.

Holub BJ, Arnott K, Davis JP, Nagpurkar A, Peschell J (2002) Organosulfur compounds from garlic. In: Shi J, Mazza G, Maguer M (eds) Functional foods, biochemical and processing aspects. CRC Press, USA, pp 214–231

13.

Berginc K, Uršič D, Žakelj S, Kristl A (2009) Aged garlic extract stimulates P-glycoprotein and multidrug resistance associated protein 2 mediated effluxes. Biol Pharm Bull 32:694–699CrossRef

14.

Rosen RT, Hiserodt RD, Fukuda EK, Ruiz RJ, Zhou Z, Lech J, Rosen SL, Hartman TG (2001) Determination of allicin, S-allylcysteine and volatile metabolites of garlic in breath, plasma or simulated gastric fluids. J Nutr 131(3S):968S–971S

15.

Amagase H, Petesch BL, Matsuura H, Kasuga S (2001) Intake of garlic and its bioactive components. J Nutr 131(S3):955S–962S

16.

Shapiro AB, Ling V (1997) Positively cooperative sites for drug transport by P-glycoprotein with distinct drug specificities. Eur J Biochem 250:130–137CrossRef

17.

Yu DK (1999) The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions. J Clin Pharmacol 39:1203–1211CrossRef

18.

Zhao YH, Abraham MH, Le J, Hersey A, Luscombe CN, Beck G, Sherborne B, Cooper I (2002) Rate-limiting steps of human oral absorption and QSAR studies. Pharm Res 19:1446–1457CrossRef

19.

Su SF, Huang JD (1996) Inhibition of intestinal digoxin absorption and exsorption by quinidine. Drug Metab Dispos 24:142–147

20.

Soldner A, Benet LZ, Mutschler E, Christians U (2000) Active transport of the angiotensin-II antagonist losartan and its main metabolite EXP 3174 across MDCK-MDR1 and Caco-2 cell monolayers. Br J Pharmacol 129:1235–1243CrossRef

21.

Yamashiro W, Maeda K, Hirouchi M, Adachi Y, Hu Z, Sugiyama Y (2006) Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptors in humans. Drug Metab Dispos 34:1247–1254CrossRef

22.

Bakos E, Evers R, Sinko E, Varadi A, Borst P, Sarkadi B (2000) Interactions of the human multidrug resistance proteins MRP1 and MRP2 with organic anions. Mol Pharmacol 57:760–768

23.

Wang E, Casciano CN, Clement RP, Johnson WW (2001) HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein. Pharm Res 18:800–806CrossRef

24.

Varma MVS, Sateesh K, Panchagnula R (2004) Functional role of P-glycoprotein in limiting intestinal absorption of drugs: contribution of passive permeability to P-glycoprotein mediated efflux transport. Mol Pharm 2:12–21CrossRef

25.

Zamek-Gliszczynski MJ, Hoffmaster KA, Humphreys JE, Tian X, Nezasa K, Brouwer KLR (2006) Differential involvement of Mrp2 (Abcc2) and Bcrp (Abcg2) in biliary excretion of 4-methylumbelliferyl glucuronide and sulphate in the rat. JPET 319:459–467CrossRef

26.

Žakelj S, Šturm K, Kristl A (2006) Ciprofloxacin permeability and its active secretion through rat small intestine in vitro. Int J Pharm 313:175–180CrossRef

27.

Guidance for industry bioavailability and bioequivalence studies for orally administered drug products — general considerations. Food and Drug Administration, Center for Drug evaluation and Research (CDER). Available via DIALOG http://www.fda.gov/cder/guidance/index.htm

28.

Maclean C, Moenning U, Reichel A, Fricker G (2008) Closing the gaps–A full scan of the intestinal expression of Pgp, Bcrp and Mrp2 in male and female rats. Drug Metab Dispos 36:1249–1254CrossRef

29.

Lee E, Ryan S, Birmingam B, Zalikowski J, March R, Ambrose H, Moore R, Lee C, Chen Y (2005) Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther 78:330–341CrossRef

30.

Steffansen B, Nielsen CU, Brodin B, Eriksson AH, Andersen R, Frokjaer S (2004) Intestinal solute carriers: an overview of trends and strategies for improving oral drug absorption. Eur J Pharm Sci 21:3–16CrossRef

31.

Faria TN, Timoszyk JK, Stouch TR, Vig BS, Landowski CP, Amidon GL, Weaver CD, Wall DA, Smith RL (2003) A novel high-throughput Pept1 transporter assay differentiates between substrates and antagonists. Mol Pharm 1:67–76CrossRef

32.

Kivistö KT, Niemi M (2007) Influence of drug transporter polimorphism on pravastatin pharmacokinetics in humans. Pharm Res 24:239–247CrossRef

33.

Katsura T, Inui KI (2003) Intestinal absorption of drugs mediated by drug transporters: mechanisms and regulation. Drug Metab Pharmacokinet 18:1–15CrossRef

34.

Sha X, Yan G, Wu Y, Li J, Fang X (2005) Effect of self-emulsifying drug delivery systems containing Labrasol on tight junctions in Caco-2 cells. Eur J Pharm Sci 24:477–486CrossRef

35.

Rahman K, Lowe GM (2006) Garlic and cardiovascular disease: a critical review. J Nutr 136(3):736S–740S

36.

Flesch G, Muller PL (1997) Absolute bioavailability and pharmacokinetics of valsaratn, an angiotensin II receptor antagonist, in man. Eur J Clin Pharmacol 52:115–120CrossRef

37.

Lo MW, Goldberg MR, McCrea JB, Lu H, Furtek C, Bjornsson TD (1995) Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans. Clin Pharmacol Ther 58:641–649CrossRef

38.

Ebert B, Seidel A, Lampen A (2005) Identification of BCRP as transporter of benzo[a]pyrene conjugates metabolically formed in Caco-2 cells and its induction by Ah-receptor agonists. Carcinogenesis 26:1754–1763CrossRef

39.

Heimeur A, Conseil G, Deeley RG, Cole SPC (2004) The MRP-related and BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation. Current drug metabolism 5:21–53CrossRef

40.

Huang L, Wang Y, Grimm S (2006) ATP-dependent transport of rosuvastatin in membrane vesicles expressing breast cancer resistance protein. Drug Metab Dispos 34:738–743CrossRef

41.

Masereel B, Pochet L, Laeckmann D (2003) An overview of inhibitors of Na/H exchanger. Eur J Med Chem 38:547–554CrossRef

42.

Anderle P, Huang Y, Sadee W (2004) Intestinal membrane transport of drugs and nutrients: genomics of membrane transporters using expression microarrays. Eur J Pharm Sci 21:17–24CrossRef

43.

Gupta N, Martin PM, Miyauchi S, Ananth S, Herdman AV, Martindale RG, Podolsky R, Ganapathy V (2006) Down-regulation of BCRP/ABCG2 in colorectal and cervical cancer. BBRC 343:571–577

44.

Shin HS, Bae SK, Lee MG (2006) Pharmacokinetics of sildenafil after intravenous and oral administration of rats: hepatic and intestinal first-pass effects. Int J Pharm 320:64–70CrossRef

45.

Halestrap AP, Meredith D (2004) The SLC16 gene family-from monocarboxylate transporters (MCTs) to aromatic amino acid transporters and beyond. Pflugers Arch 447(5):619–628CrossRef

46.

Gill RK, Saksena S, Alrefai WA, Sarwar Z, Goldstein JL, Carroll RE, Ramaswamy K, Dudeja PK (2005) Expression and membrane localization of MCT isoforms along the length of human intestine. Am J Physiol Cell Physiol 289:C846–C852CrossRef

Titel: In vitro interactions between aged garlic extract and drugs used for the treatment of cardiovascular and diabetic patients
verfasst von: Katja Berginc
Simon Žakelj
Albin Kristl
Publikationsdatum: 01.09.2010
Verlag: Springer-Verlag
Erschienen in: European Journal of Nutrition / Ausgabe 6/2010
Print ISSN: 1436-6207
Elektronische ISSN: 1436-6215
DOI: https://doi.org/10.1007/s00394-010-0095-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

In vitro interactions between aged garlic extract and drugs used for the treatment of cardiovascular and diabetic patients

Abstract

Background

Aim

Methods

Results

Conclusions

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Abstract

Background

Aim

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2010

trans Fatty acid consumption, lifestyle and type 2 diabetes prevalence in a Spanish population

Fructose and saturated fats predispose hyperinsulinemia in lean male rat offspring

Effects of Mediterranean diets with low and high proportions of phytate-rich foods on the urinary phytate excretion

Folates in bread: retention during bread-making and in vitro bioaccessibility

Competitive inhibition of carotenoid transport and tissue concentrations by high dose supplements of lutein, zeaxanthin and beta-carotene

Bilberry juice modulates plasma concentration of NF-κB related inflammatory markers in subjects at increased risk of CVD

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin